Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAM17 | P78536 | 9/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.40 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077366 | 1.00 | ADAM17 (0.52) | ADAM17HTR2CATML3MBTL1NTRK3 | |
| SCHEMBL2823324 | 0.86 | ATM (0.56) | ADAM17ATML3MBTL1 | |
| SCHEMBL11075435 | 0.83 | ADAM17 (0.49) | ADAM17ATML3MBTL1 | |
| SCHEMBL11078762 | 0.82 | ADAM17 (0.47) | ADAM17HTT | |
| SCHEMBL11470653 | 0.82 | ADAM17 (0.42) | ADAM17 | |
| SCHEMBL3984092 | 0.79 | ADAM17 (0.53) | ADAM17 | |
| SCHEMBL4776144 | 0.78 | HTR2C (0.57) | HTR2C | |
| SCHEMBL11082553 | 0.78 | ADAM17 (0.45) | ADAM17 | |
| SCHEMBL15607721 | 0.77 | HTR2C (0.56) | HTR2C | |
| SCHEMBL19860381 | 0.77 | HTR2C (0.56) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879578-A4 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2009-05-13 | — | — | EP | disclosed |
| EP-1879578-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV Pharmaceutical Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | DOV PHARMACEUTICAL, INC. | 2008-01-10 | — | — | US | disclosed |
| EP-1807071-A4 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL INC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1807071-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV Pharmaceutical Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006102029-A9 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL INC (US) | 2006-12-07 | — | — | WO | disclosed |
| WO-2006102029-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF URINARY INCONTINENCE | DOV PHARMACEUTICAL, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20060100263-A1 | Antipyretic compositions and methods | DOV PHARMACEUTICAL, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006050520-A2 | ANTIPYRETIC COMPOSITIONS AND METHODS | DOV PHARMACEUTICAL, INC. (US) | 2006-05-11 | — | — | WO | disclosed |
| US-4435419-A | Method of treating depression using azabicyclohexanes | AMERICAN CYANAMID COMPANY (US) | 1984-03-06 | — | — | US | disclosed |
| US-4231935-A | ANXIOLYTICS AND ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-11-04 | — | — | US | disclosed |
| US-4196120-A | 1,2-BIS(HYDROCARBYLSULFONYLOXY OR HALO METHYL)CYCLOPROPYLBENZENE, OPTICAL ACITIVITY ANALGESICS | AMERICAN CYANAMID COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4131611-A | ANXIOLYTIC, ANALGESIC | AMERICAN CYANAMID COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009538-A1 | Methods and compositions for the treatment of urinary incontinence | BPHL, MYOF, NISCH | ADAM17 621/4885HTR2C 2154/4885ATM 4109/4885 |
| US-20060100263-A1 | Antipyretic compositions and methods | GABRE, HTR5A, TPH2 | ADAM17 1887/4885HTR2C 16/4885ATM 2216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.